| 引用本文: | 朱雪萍,张丽梅,毛信心,师帅,胡元会,刘美含,蒋雨辰,李晓宁.丹参川芎嗪注射液对心绞痛疗效及血脂影响的meta分析[J].中国现代应用药学,2022,39(5):638-647. |
| ZHU Xueping,ZHANG Limei,MAO Xinxin,SHI Shuai,HU Yuanhui,LIU Meihan,JIANG Yuchen,LI Xiaoning.Meta-analysis of Blood Lipid Level in the Treatment of Angina Pectoris with Salvia Miltiorrhiza Ligustrazine Hydrochloride Injection[J].Chin J Mod Appl Pharm(中国现代应用药学),2022,39(5):638-647. |
|
| |
|
|
| 本文已被：浏览 1258次 下载 455次 |
码上扫一扫！ |
|
|
| 丹参川芎嗪注射液对心绞痛疗效及血脂影响的meta分析 |
|
朱雪萍, 张丽梅, 毛信心, 师帅, 胡元会, 刘美含, 蒋雨辰, 李晓宁
|
|
中国中医科学院广安门医院心血管科, 北京 100053
|
|
| 摘要: |
| 目的 评价丹参川芎嗪注射液治疗心绞痛的疗效及其对血脂水平的影响。方法 计算机检索Cochrane Library、Pubmed、Embase、知网、万方、维普等数据库，检索时限均为建库至2021年2月19日。由2名研究者独立筛选文献、提取资料并评价偏倚风险，采用Review Manager 5.3软件进行meta分析。结果 共纳入16项研究，包括1 631例患者。Meta分析结果显示，与西药常规疗法相比，联合丹参川芎嗪注射液治疗心绞痛总疗效[OR=3.88，95% CI(2.80，5.37)，P<0.000 01]更好。血清总胆固醇水平[MD=–1.08，95%CI(–1.36，–0.81)，P<0.000 01]、甘油三酯水平[MD=–0.52，95%CI (–0.66，–0.37)，P<0.000 01]、低密度脂蛋白水平[MD=–0.74，95%CI(–0.94，–0.55)，P<0.000 1]低于对照组；高密度脂蛋白水平高于对照组[MD=0.28，95%CI(0.20，0.36)，P<0.000 01]。不良反应发生率亦低于对照组[OR=0.57，95%CI(0.30，1.08)，P=0.008]。结论 联合使用丹参川芎嗪注射液治疗心绞痛疗效明确，能有效改善血脂且不增加不良反应发生率。 |
| 关键词: 丹参川芎嗪注射液 心绞痛 血脂 meta分析 |
| DOI：10.13748/j.cnki.issn1007-7693.2022.05.011 |
| 分类号:R969.3 |
| 基金项目:国家重点研发计划项目（2019YFC1708400）；国家中医药管理局-国家中医药领军人才支持计划“岐黄学者”项目（0201000402） |
|
| Meta-analysis of Blood Lipid Level in the Treatment of Angina Pectoris with Salvia Miltiorrhiza Ligustrazine Hydrochloride Injection |
|
ZHU Xueping, ZHANG Limei, MAO Xinxin, SHI Shuai, HU Yuanhui, LIU Meihan, JIANG Yuchen, LI Xiaoning
|
|
Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
|
| Abstract: |
| OBJECTIVE To evaluate the efficacy and safety of Salvia Miltiorrhiza Ligustrazine Hydrochloride injection in the treatment of angina pectoris and its effect on hyperlipidaemia. METHODS Cochrane Library, Pubmed, Embase, CNKI, WanFang Data, VIP and other databases were searched by computer, and the searched time was from the database to February 19, 2021. Two researchers independently screened the literature, extracted the data and evaluated the risk of bias. Meta-analysis was performed by RevMan5.3 software.RESULTS Sixteen randomized controlled trials with 1 631 patients were included. The results of meta analysis showed that, compared with conventional western medicine, combined with Salvia Miltiorrhiza Ligustrazine Hydrochloride injection had better total efficacy[OR=3.88, 95% CI(2.80, 5.37), P<0.000 01] in the treatment of angina. The levels of total cholesterol[MD=-1.08, 95%CI(-1.36, -0.81), P<0.000 01], total triglyceride[MD=-0.52, 95%CI(-0.66, -0.37), P<0.000 01] and low density lipoprotein[MD=-0.74, 95%CI(-0.94, -0.55), P<0.000 1] in Salvia Miltiorrhiza Ligustrazine Hydrochloride injection group were lower than those in control group. The level of high density lipoprotein in Salvia Miltiorrhiza Ligustrazine Hydrochloride injection group was higher than that in control group[MD=0.28, 95%CI(0.20, 0.36), P<0.000 01]. The incidence of adverse reactions of Salvia Miltiorrhiza Ligustrazine Hydrochloride injection group was lower than that of the control group[OR=0.57, 95%CI(0.30, 1.08), P=0.008].CONCLUSION Treatment combined with Salvia Miltiorrhiza Ligustrazine Hydrochloride injection has significant curative effect on angina pectoris and can effectively improve blood lipid level without increasing the incidence of adverse reactions. |
| Key words: Salvia Miltiorrhiza Ligustrazine Hydrochloride injection angina pectoris blood lipid meta-analysis |
|
|
|
|
